Sofosbuvir/Velpatasvir (SOF/VEL)

DRUG4 trials

Sponsors

Gilead Sciences, Johns Hopkins University, Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, Médecins du Monde

Conditions

HCV CoinfectionHIVHIV-1-infectionHepatitis CHepatitis C Virus InfectionLiver DiseaseLiver DiseasesRDT

Early Phase 1

Simplifying Hepatitis C Pathways for People Who Inject Drugs in Armenia, Georgia, and Tanzania

RecruitingNCT06159504

Médecins du MondeHepatitis C, RDT

Start: 2024-10-03End: 2026-12-31Target: 3040Updated: 2025-07-18

Phase 4

deLIVER: Direct Acting Antiviral Effects on the Liver

CompletedNCT02938013

Johns Hopkins UniversityHCV Coinfection, HIV, Liver Disease

Start: 2017-01-31End: 2020-09-30Updated: 2022-02-24

Monitoring SOF/VEL in Treatment Naïve, HCV Participants With Active Infection

CompletedNCT03512210

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsHepatitis C, HIV-1-infection, Liver Diseases

Start: 2018-10-22End: 2021-02-28Updated: 2022-02-04

Unknown Phase

A Registry for Adolescent and Pediatric Participants Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials

TerminatedNCT02510300

Gilead SciencesHepatitis C Virus Infection

Start: 2015-10-21End: 2023-01-06Updated: 2023-01-27

Related Papers

Non-randomised trial of a hepatitis C same-day test and treat model using antibody test only for people who inject drugs in Armenia, Georgia and Tanzania: a CUTTS HepC study protocol.

2026-03-24

Reinfection and Resistance Associated Substitutions Following a Minimal Monitoring Approach for Hepatitis C Virus Treatment in MINMON Trial.

2025-07-01

Long-term efficacy and safety of sofosbuvir-based direct-acting antiviral regimens in paediatric patients with hepatitis C virus infection: an international registry study.

2025-04-013 citations

Impact of a minimal monitoring HCV treatment approach on Health-Related Quality of Life.

2025-02-28

Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation

The Journal of Infectious Diseases2024-12-041 citations

Second-Phase Hepatitis C Plasma Viral Kinetics Directly Reflects Reduced Intrahepatic Burden of Hepatitis C Virus

The Journal of Infectious Diseases2023-02-012 citations

Perspectives on Adherence From the ACTG 5360 MINMON Trial: A Minimum Monitoring Approach With 12 Weeks of Sofosbuvir/Velpatasvir in Chronic Hepatitis C Treatment

Clinical Infectious Diseases2023-01-2412 citations

A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.

2022-01-1084 citations